Titan Pharmaceuticals, Inc. (TTNP)
NASDAQ: TTNP · Real-Time Price · USD
5.66
-0.04 (-0.70%)
Sep 18, 2024, 4:00 PM EDT - Market closed

Company Description

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally.

It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.

The company was founded in 1991 and is based in South San Francisco, California.

Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals logo
Country United States
Founded 1991
IPO Date Jan 18, 1996
Industry Biotechnology
Sector Healthcare
Employees 4
CEO David Lazar

Contact Details

Address:
400 Oyster Point Boulevard, Suite 505
South San Francisco, California 94080
United States
Phone 650 244 4990
Website titanpharm.com

Stock Details

Ticker Symbol TTNP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000910267
CUSIP Number 888314606
ISIN Number US8883147055
Employer ID 94-3171940
SIC Code 2836

Key Executives

Name Position
Jennifer Kiernan Executive Assistant to Chief Executive Officer and Investor Communications Coordinator
David Elliot Lazar Chief Executive Officer and Principal Financial Officer
Dr. Katherine L. Beebe-DeVarney Ph.D. President, Chief Operating Officer and Director
Mike Fritz National Sales Director
Joe Schrei Executive Director of Commercial Operations

Latest SEC Filings

Date Type Title
Aug 21, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Aug 19, 2024 425 Filing
Aug 19, 2024 8-K Current Report
Aug 15, 2024 10-Q Quarterly Report
Aug 15, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
May 15, 2024 10-Q Quarterly Report
Apr 26, 2024 RW Filing
Apr 5, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Apr 3, 2024 8-K Current Report
Apr 1, 2024 10-K Annual Report